Alzamend Neuro, Inc. Q3 2026 Financial Results: Key Highlights for Investors

Overview

Alzamend Neuro, Inc. (NASDAQ: ALZN), a clinical-stage biopharmaceutical company, has released its unaudited financial results for the quarter ended January 31, 2026. The company remains focused on developing novel treatments for neurodegenerative diseases and mental health disorders.

Key Financial Highlights

• Net Loss: For the three months ended January 31, 2026, Alzamend reported a net loss available to common shareholders of (\$2,198,991). For the nine months ended January 31, 2026, the net loss was (\$5,902,433).
• Basic and Diluted Net Loss Per Share: For the same quarterly period, the basic and diluted net loss per share was (\$0.58), reflecting continued losses as the company invests in R&D and clinical progress.
• Shares Outstanding: As of January 31, 2026, there were 3,804,741 shares of common stock outstanding.
• Stockholders’ Equity: Stockholders’ equity stood at \$2,184,505 at quarter-end, indicating a positive equity position despite ongoing operating losses.
• Preferred Stock Activity: The company had no Series B Convertible Preferred Stock outstanding as of January 31, 2026. There were conversions of preferred stock to common stock during the period, impacting the capital structure.
• Capital Raises: In the comparative period (nine months ended January 31, 2025), the company raised \$688,700 through the issuance of common stock for cash (net of issuance costs), highlighting its reliance on equity financing.

Other Notable Items

• Dividends: There were no dividends paid on preferred shares during the most recent quarter, but there was a dividend of \$33,728 on Series A Preferred during Q3 in the prior year.
• Stock-Based Compensation: The company continued to record expenses for stock-based compensation to employees and consultants, a non-cash charge that affects the bottom line.
• Regulatory Filing Status: Alzamend has filed all reports required under Section 13 or 15(d) of the Securities Exchange Act and is in compliance with its reporting obligations.
• Company Classification: Alzamend is identified as a non-accelerated filer, smaller reporting company, and emerging growth company. These statuses provide certain regulatory reliefs but also indicate the company’s developmental stage.
• NASDAQ Capital Market Listing: The company’s common stock continues to be traded on the NASDAQ Capital Market under the symbol ALZN.

Items Potentially Impacting Share Price

• Ongoing Losses: Persistent net losses and negative earnings per share are likely to weigh on investor sentiment and may pressure the stock unless offset by clinical or partnership news.
• Capital Structure Changes: The conversion of preferred stock to common stock and new equity issuances may result in dilution for existing shareholders, which can impact share price.
• Financing Needs: With ongoing R&D costs and limited revenue, the company may need to raise additional capital, which could further dilute shareholders or require debt financing.
• Stockholder Equity: The positive equity position is a sign of some balance sheet strength but must be monitored closely given ongoing losses.

Conclusion

The latest quarterly report from Alzamend Neuro, Inc. highlights the company’s ongoing commitment to R&D and its status as a development-stage biotech with ongoing losses and a reliance on equity financing. Investors should closely monitor future capital raises, dilution, and any pivotal clinical or regulatory milestones that could alter the company’s financial trajectory and impact the share price.

Disclaimer: This article is for informational purposes only and does not constitute investment advice. Investors should review the company’s full filings and consult their financial advisor before making investment decisions. The company is a development-stage biotech with significant risks, including ongoing losses and the need for additional financing.

View Alzamend Neuro, Inc. Historical chart here